PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis

被引：0
|
作者：
Schettini, F. [1 ]
Pascual, T. [1 ]
Chic, N. [1 ]
Conte, B. [2 ]
Martinez, O. [1 ]
Adamo, B. [1 ]
Vidal, M. [1 ]
Munoz, M. [1 ]
Fernandez-Martinez, A. [3 ]
Griguolo, G. [4 ]
Guarneri, V. [4 ]
Conte, P. F. [4 ]
De Placido, S. [5 ]
Carey, L. [6 ]
Perou, C. M. [7 ]
Prat, A. [1 ]
机构：
[1] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[2] Univ Genoa, Osped Policlin San Martino, Med Oncol, Genoa, Italy
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol, Padua, Italy
[5] Azienda Univ Osped Federico II, Clin Med & Surg, Naples, Italy
[6] UNC, Lineberger Canc Ctr, Med, Div Hematol Oncol, Chapel Hill, NC USA
[7] UNC, Lineberger Canc Ctr, Genet, Chapel Hill, NC USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy
    Stjepanovic, Neda
    Kumar, Sudhir
    Jerzak, Katarzyna J.
    Trudeau, Maureen
    Warner, Ellen
    Cao, Xingshan
    Eisen, Andrea
    Tran, William
    Pezo, Rossanna C.
    CLINICAL BREAST CANCER, 2024, 24 (08) : e723 - e730
  • [42] Management of HER2-Positive Early Breast Cancer
    Steger, Guenther
    Lueftner, Diana
    Stoeger, Herbert
    Thurlimann, Beat
    Untch, Michael
    BREAST CARE, 2018, 13 (06) : 453 - 455
  • [43] PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.
    Gomez Pardo, P.
    Prat, A.
    Bianchini, G.
    Pickl, M.
    Belousov, A.
    Koehler, A.
    Semiglazov, V.
    Eiermann, W.
    Tjulandin, S.
    Biakhov, M.
    Lluch, A.
    Zambetti, M.
    Vazquez-Mazon, F.
    Gianni, L.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis
    Hu, Wenyu
    Yang, Jixin
    Zhang, Ze
    Xu, Dongdong
    Li, Nanlin
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (02) : 247 - +
  • [45] The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer
    Nakashoji, Ayako
    Hayashida, Tetsu
    Yokoe, Takamichi
    Maeda, Hinako
    Toyota, Tomoka
    Kikuchi, Masayuki
    Watanuki, Rurina
    Nagayama, Aiko
    Seki, Tomoko
    Takahashi, Maiko
    Abe, Takayuki
    Kitagawa, Yuko
    CANCER TREATMENT REVIEWS, 2018, 62 : 9 - 17
  • [46] Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort
    Sanchez Bayona, R.
    Tolosa, P.
    Alba Bianchi, M.
    Madariaga Urrutia, A.
    Teran, S.
    Rey Cardenas, M.
    Lema Roso, L.
    Ruano, Y.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2022, 33 : S143 - S144
  • [47] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [48] Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
    Teran, Santiago
    Alva, Manuel
    Tolosa, Pablo
    Rey-Cardenas, Macarena
    Madariaga, Ainhoa
    Lema, Laura
    Ruano, Yolanda
    Manso, Luis
    Ciruelos, Eva
    Sanchez-Bayona, Rodrigo
    BREAST, 2023, 71 : 42 - 46
  • [49] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [50] Rate of pathological complete response in early HER2 breast cancer
    Bodet, Marie-Lucile
    Rouzier, Roman
    Hequet, Delphine
    BULLETIN DU CANCER, 2022, 109 (06) : 722 - 723
12345